Adoptive Transfer of ILC2s into the Brain Reveals Tumor Homing in Glioblastoma: A Proof-of-Concept for Cellular Therapy
Wang, L. P.; Bhandari, B.; Naeini, S. E.; Yu, J. C.; Arbab, A. S.; Young, N.; Salles, E. L.; Baban, B.
Show abstract
Glioblastoma (GBM) is an aggressive brain tumor with limited treatment options and poor immune cell infiltration. Cellular immunotherapies have transformed cancer treatment but remain largely ineffective against GBM due to the restrictive blood-brain barrier (BBB) and its profoundly immunosuppressive microenvironment. Innate lymphoid cells type 2 (ILC2s) have recently emerged as potential candidates for cellular immunotherapy because of their regenerative and immunomodulatory functions. Here, we provide the first in vivo evidence that systemically administered ILC2s can cross the BBB and home to glioblastoma. Bone marrow-derived ILC2s from C57BL/6 mice were labeled with CFSE and intravenously transferred into hosts bearing orthotopic, luciferase-expressing GL261 tumors. Fluorescence imaging and flow cytometry analyses indicated that transferred ILC2s successfully entered the brain, localized within tumor tissue, and were also detected in meninges and peripheral organs. Although no measurable reduction in tumor growth was observed, these findings support a proof-of-concept for adoptive ILC2 transfer as a feasible approach for targeting CNS tumors and exploring their immunomodulatory potential in GBM.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Oncolytic HSV-IL27 expression improves CD8 T cell function and therapeutic activity in syngeneic glioma models 94%
- GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma 94%
- Development of GPC2-directed chimeric antigen receptors using mRNA for pediatric brain tumors 94%
Similar papers in this journal
- CD4+ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts 94%
- Antibody Targeting of B7-H4 Enhances the Immune Response in Urothelial Carcinoma 93%
- Immuno-Phenotyping of High-Grade Glioma Infiltrating Immune Cells Reveals Grade Specific Differences in Cells of Myeloid Origin 93%
Similar papers in this journal
- PTPRZ1-targeting RNA CAR-T cells exert antigen-specific and bystander antitumor activity in glioblastoma 94%
- The conventional dendritic cell 1 subset primes CD8+ T cells and traffics tumor antigen to drive anti-tumor immunity in the brain 94%
- Immune modulation of innate and adaptive responses restores immune surveillance and establishes anti-tumor immunological memory 93%
Similar papers in this journal
- Armored Bicistronic CAR T Cells with Dominant-negative TGF-β Receptor II to Overcome Resistance in Glioblastoma. 95%
- Pre-conditioning Modifies the Tumor Microenvironment to Enhance Solid Tumor CAR T Cell Efficacy and Endogenous Immunity 93%
- Balancing activation and costimulation of CAR tunes signaling dynamics and enhances therapeutic potency 93%
Similar papers in this journal
- STING activation counters glioblastoma by vascular alteration and immune surveillance 93%
- IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumors 93%
- Novel EGFR-Mutant Mouse Models of Lung Adenocarcinoma Reveal Adaptive Immunity Requirement for Durable Osimertinib Response 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.